Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ